SRSF2 mutations have been found in 28–47% of patients with CMML and about 14% of patients with MDS [32] and have been associated with increased age, higher levels of hemoglobin, and normal cytogenetics. This evidence concerns the gene SRSF2 and chronic myelomonocytic leukemia.